fulness of breath will, as community prevalence of COVID-19, to date neither neutropenia nor agranulocytosis is.

In the absence of an antibody test for COVID-19 we rely on reverse-transcriptase polymerase chain reaction COVID-19 testing, which does not have 100% sensitivity in the initial phase of infection, so a single negative test does not exclude infection. Once an antibody test becomes available it will be a useful addition to pre-clozapine investigations.

Comorbidities such as diabetes, hypertension, respiratory illness and cardiovascular disease are very common in patients taking clozapine but are associated with adverse outcomes in the event of COVID-19 infection, including increased mortality rates. It is not known whether the antibody deficiency described in patients taking clozapine will further compromise this vulnerable group. These are not, however, indications to stop clozapine, which itself has serious adverse consequences. Rather patients need clear advice and, if possible, assistance regarding self-isolation and other precautions advised. Obesity and sleep apnoea may also contribute to poor outcomes and continuous positive airway pressure treatment, which can be an aerosol-generating procedure, may be a risk to staff.

Individuals already established on clozapine and managed in the community may require changes to their management. In view of recommendations for social distancing, the use of clozapine clinics for routine blood testing should be reconsidered. Instead, blood tests may be better performed in patient’s homes, with staff using personal protective equipment and at, or near, the maximum intervals permitted. While the standard blood monitoring frequencies are at weekly (weeks 1–18), fortnightly (weeks 19–52) and four-weekly (over 52 weeks) intervals, clozapine can still be dispensed and administered with satisfactory monitoring at 14-, 21- and 42-day intervals, respectively.

Inevitably many patients taking clozapine will present with flu-like symptoms. An urgent full blood count will be required to exclude neutropenia with appropriate action. Many, however, will have another cause and so the evolving National Health Service recommendations regarding isolation and hopefully testing for COVID-19 infection should be followed. The combination of flu-like symptoms, chest pain and shortness of breath will, as community prevalence of COVID-19 increases, be much more likely to be because of COVID-19 than clozapine-induced myocarditis, except perhaps within the first 60 days of treatment. However, such a presentation will still need investigation and cessation of clozapine may on occasion be required as well as urgent general medical assistance. Careful documentation of symptom profiles and investigations will aid subsequent decisions regarding clozapine re-challenge. In the event of COVID-19 infection the acute-phase reaction may result in reduced activity of cytochrome P450 1A2, raising clozapine levels and so an urgent trough clozapine level will be needed with a reduction in clozapine dose if required. This effect may be amplified if hospital admission is indicated necessitating abrupt change in smoking habits.

In summary, COVID-19 presents us with extreme difficulties regards clozapine initiation, the risks of COVID-19 are insufficient to justify stopping clozapine, an action which presents its own serious problems, precautions must be taken now to help protect our high-risk patients as COVID-19 infection may jeopardise both their physical and mental health.

Edward Silva, Consultant Psychiatrist, Ashworth Hospital, Mersey Care NHS Foundation Trust, UK; email: ed.silva@merseycare.nhs.uk; Siobhan Goo, Principal Pharmacist, South London and Maudsley NHS Foundation Trust, Maudsley Hospital, UK; Shubulade Smith, Consultant Psychiatrist, South London and the Maudsley NHS Foundation Trust and Visiting Senior Lecturer, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK; Fiona Gaughran, Consultant Psychiatrist, National Psychosis Unit, South London and the Maudsley NHS Foundation Trust and Reader, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK.

Declaration of interest
F.G. has received honoraria for advisory work and lectures or continuing medical education activity support from Roche, BMS, Lundbeck, Otsuka, Janssen and Sunovion, is a collaborator on an NHS Innovations project co-funded by Janssen and has a family member with professional links to Lilly and GSK, including shares. E.S. has received speaker fees from Janssen and Novartis.

1. Xiang Y-T, Zhao Y-J, Liu Z-H, Li X-H, Zhao N, Cheung T, et al. The COVID-19 outbreak and psychiatric hospitals in China: managing challenges through mental health service reform. Intern J Biol Sci 2020; 16: 1741–4.
2. Roge R, Moller BK, Andersen CR, Correll CU, Nielsen J. Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res 2012; 140: 204–13.
3. Maharaj R. King’s Critical Care - Evidence Summary Clinical Management of COVID-19. King’s College Hospital NHS Foundation Trust, 2020.
4. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, et al. COVID-19 outbreak and psychiatric hospitals in China: managing challenges through mental health service reform. Intern J Biol Sci 2020; 16: 1741–4.
5. Ponsford M, Castle D, Tahir T, Robinson R, Wade W, Steven R, et al. Clozapine is associated with secondary antibody deficiency. Br J Psychiatry 2019; 214: 83–9.
6. Genta PR, Lorenzi-Filho G. Sealing the leak: a step forward in improving CPAP adherence. Chest 2018; 153: 774–5.
7. Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ. Clinical course and analysis of ten fatal cases of clozapine-induced myocarditis and comparison with 66 surviving cases. Schizophr Res 2011; 128: 161-5.

doi:10.1192/bjb.2020.66

© The Author(s) 2020. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Standing with our medical colleagues
Like many of us I am increasingly concerned about the possible effects of coronavirus on myself, my family and our community and patients. With family in Italy, I am mindful of the need there for other medical professionals to be brought in to work alongside their acute medical colleagues. This has included those more distant from acute medical work now, such as pathologists and even in some cases psychiatrists.
Little has been spoken about our role in regards to COVID-19 should we see similar scenes here in the UK and what our possible involvement might be. It would be easy to adopt a ‘protectionist’ attitude and leave the messy stuff to ‘real doctors’.

As a psychiatrist, I am a doctor of the mind and body. Of course, I would never advocate working beyond our professional competencies; however, I feel we have a strong duty to stand beside our medical colleagues be it pushing trolleys, taking blood or sweeping floors if the need arises. We spend so much time and energy trying to reduce the splitting that occurs between ‘medicine’ and ‘psychiatry’; surely we cannot hide behind this very split now when our colleagues and indeed our communities may need us if an outbreak worsens to the degree that many fear. Surely then we must stand together as one profession.

Sarah Castle, ST6 Doctor in Child and Adolescent Psychiatry, Tavistock and Portman NHS Foundation Trust, UK; email: sarah.castle@yahoo.co.uk

Declaration of interest

None.

doi:10.1192/bjb.2020.67

© The Author(s) 2020. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.